J. Lowe

发表

Network biology as a new approach to drug discovery.

David M. Wilson, J. Lowe, Phil Jones, 2010, Current opinion in drug discovery & development.

Faculty Opinions recommendation of When quality beats quantity: decision theory, drug discovery, and the reproducibility crisis.

J. Lowe, 2016 .

Molecular basis for the species selectivity of the substance P antagonist CP-96,345.

J. Lowe, J. Krause, B. Sachais, 1993, The Journal of biological chemistry.

Structure-activity relationship of quinazolinedione inhibitors of calcium-independent phosphodiesterase.

J. Lowe, D. Helweg, J. Chen, 1991, Journal of medicinal chemistry.

Chapter 13. Mechanisms of Antibiotic Resistance

J. Lowe, 1982 .

Characterization of Non-peptide Antagonist and Peptide Agonist Binding Sites of the NK1 Receptor with Fluorescent Ligands*

G. Turcatti, J. Lowe, T. Schwartz, 1997, The Journal of Biological Chemistry.

In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity.

J. Lowe, M. Aceto, D. R. Compton, 1996, The Journal of pharmacology and experimental therapeutics.

Atypical antipsychotics—recent findings and new perspectives

J. Lowe, T. Seeger, F. J. Vinick, 1988, Medicinal research reviews.

Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A.

J. Lowe, M. Aceto, B. Martin, 1995, European journal of pharmacology.

Chapter 30. Progress in the Characterization of Peptide Receptors

J. Lowe, 1990 .

CP-96,345 antagonism of NK1 receptors and smoke-induced protein extravasation in relation to its cardiovascular effects.

A. Franco‐Cereceda, J. Lowe, C. Clingan, 1992, European journal of pharmacology.

Binding epitopes for peptide and non-peptide ligands on the NK1 (substance P) receptor

S. Nakanishi, J. Lowe, T. Schwartz, 1992, Regulatory Peptides.

Chapter 11. The Role of Tachykinins in Pulmonary Disease

J. Lowe, R. Snider, 1993 .

Characterization of Δ9-Tetrahydrocannabinol and Anandamide Antinociception in Nonarthritic and Arthritic Rats

J. Lowe, S. Welch, K. Fujimori, 1998, Pharmacology Biochemistry and Behavior.

Antiinflammatory and analgesic activity of CP-96,345: on orally active non-peptide substance P receptor antagonist

J. Lowe, M. Tsuchiya, Y. Kanai, 1993, Regulatory Peptides.

Antiinflammatory and analgesic activity of a non-peptide substance P receptor antagonist

J. Lowe, M. Tsuchiya, Y. Kanai, 1992, Regulatory Peptides.

The discovery of (2S,3S)-cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl)methyl]-1- azabicyclo[2.2.2]-octan-3-amine as a novel, nonpeptide substance P antagonisst.

J. Lowe, S. Zorn, S. Mclean, 1992, Journal of medicinal chemistry.

A novel series of [3.2.1] azabicyclic biaryl ethers as alpha3beta4 and alpha6/4beta4 nicotinic receptor agonists.

R. J. Mather, R. Hurst, J. Lowe, 2010, Bioorganic & medicinal chemistry letters.

Total synthesis and stereochemical assignment of (±)-Epiderstatin

J. Lowe, R. L. Dow, M. A. Hain, 1992 .

Differential SAR of quinuclidine SP antagonists between rat and human-type receptors

J. Lowe, S. Zorn, R. Snider, 1992, Regulatory Peptides.

Discovery of CP-96,345 and its characterization in disease models involving substance P

J. Lowe, S. Zorn, S. Mclean, 1992, Regulatory Peptides.

CB1 receptor antagonist precipitates withdrawal in mice exposed to Delta9-tetrahydrocannabinol.

J. Lowe, B. Martin, S. Cook, 1998, The Journal of pharmacology and experimental therapeutics.

CB 1 Receptor Antagonist Precipitates Withdrawal in Mice Exposed to D 9-Tetrahydrocannabinol 1

J. Lowe, B. Martin, S. Cook, 1998 .

Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats

R. L. Barrett, J. Lowe, B. Martin, 1995, Neuropharmacology.

Antagonism of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus monkeys.

J. Lowe, B. Martin, J. Wiley, 1995, The Journal of pharmacology and experimental therapeutics.

Preparation and radiolabelling of CP-96,345, the first non-peptide substance P antagonist

J. Lowe, J. Bordner, R. Snider, 1991 .

Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal.

J. Lowe, M. Aceto, B. Martin, 1996, The Journal of pharmacology and experimental therapeutics.

[3H]-(R)-NPTS, a radioligand for the type 1 glycine transporter.

J. Lowe, C. Strick, L. Lebel, 2003, Bioorganic & medicinal chemistry letters.

Novel inhibitors of the type 1 transporter for glycine (GlyT1) as antipsychotic agents

J. Lowe, 2005 .

Substituted 6-phenyl-pyridin-2-ylamines: selective and potent inhibitors of neuronal nitric oxide synthase.

R. Volkmann, J. Lowe, R. Nelson, 2004, Bioorganic & medicinal chemistry letters.

Cardiovascular effects of cholecystokinin-4 are mediated by the cholecystokinin-B receptor subtype in the conscious guinea pig and dog.

J. Lowe, S. Zorn, A. Fossa, 1997, The Journal of pharmacology and experimental therapeutics.

N-alkyl quinuclidinium substance P antagonists

J. Lowe, S. Mclean, J. Bordner, 1994 .

2-Aryl-1-azabicyclo[2.2.2]octanes as novel nonpeptide substance P antagonists

J. Lowe, J. Bordner, R. Snider, 1994 .

Nuclear variations of quinuclidine substance P antagonists: 2-diphenylmethyl-1-azabicyclo[3.2.2]nonan-3-amines

J. Lowe, R. Snider, S. Drozda, 1993 .

Activity and distribution of binding sites in brain of a nonpeptide substance P (NK1) receptor antagonist.

A. Ganong, J. Lowe, J. Heym, 1991, Science.

A potent nonpeptide antagonist of the substance P (NK1) receptor.

J. Lowe, M. Desai, R. Spencer, 1991, Science.

3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents.

Anne W. Schmidt, J. Lowe, P. Seymour, 1996, Journal of medicinal chemistry.

Specific residues at the top of transmembrane segment V and VI of the neurokinin-1 receptor involved in binding of the nonpeptide antagonist CP 96,345 [corrected].

J. Lowe, T. Schwartz, U. Gether, 1994, The Journal of biological chemistry.

Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.

Anne W. Schmidt, J. Lowe, P. Seymour, 1995, The Journal of pharmacology and experimental therapeutics.

5-Phenyl-3-ureidobenzazepin-2-ones as cholecystokinin-B receptor antagonists.

D. Hageman, J. Lowe, S. Zorn, 1994, Journal of medicinal chemistry.

Structure-activity relationships of potent, selective inhibitors of neuronal nitric oxide synthase based on the 6-phenyl-2-aminopyridine structure.

R. Volkmann, J. Lowe, P. Seymour, 2004, Journal of medicinal chemistry.

An improved synthesis of [1H]-isoindolin-1-one-3-carboxylic acid

J. Lowe, F. E. Ewing, 1987 .

Aza-tricyclic substance P antagonists.

J. Lowe, S. Mclean, M. Tsuchiya, 1994, Journal of medicinal chemistry.

Deoxygenation of Pyridones Via Their Tetrazolyl Ethers

J. Lowe, S. Drozda, F. E. Ewing, 1989 .

A guide to drug discovery: The role of the medicinal chemist in drug discovery — then and now

John A. Lowe, Joseph G. Lombardino, J. Lowe, 2004, Nature Reviews Drug Discovery.

Aprepitant (Emend): A NK1 Receptor Antagonist for the Treatment of Postchemotherapy Emesis

J. Lowe, 2010 .

Effect of CP-96,345, a nonpeptide substance P receptor antagonist, on salivation in rats.

J. Lowe, S. Leeman, R. Snider, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Different binding epitopes on the NK1 receptor for substance P and a non-peptide antagonist

S. Nakanishi, J. Lowe, T. Schwartz, 1993, Nature.

Two nonpeptide tachykinin antagonists act through epitopes on corresponding segments of the NK1 and NK2 receptors.

S. Nakanishi, J. Lowe, T. Schwartz, 1993, Proceedings of the National Academy of Sciences of the United States of America.

Review: Central & Peripheral Nervous System: Cholecystokinin-B receptor antagonists

J. Lowe, 1995 .

Faculty Opinions recommendation of Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.

John Lowe, J. Lowe, 2015 .

1-Naphthylpiperazine derivatives as potential atypical antipsychotic agents.

Anne W. Schmidt, J. Lowe, P. Seymour, 1991, Journal of medicinal chemistry.

Chapter 32. Applications of Recombinant DNA Technology of Interest to Medicinal Chemists

J. Lowe, P. Hobart, 1983 .

Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A.

J. Lowe, S. Welch, J. Huffman, 1998, The Journal of pharmacology and experimental therapeutics.

Discovery of CP-96,345 and its characterization in disease models involving substance P

J. Lowe, S. Zorn, S. Mclean, 1992, Regulatory Peptides.

Faculty Opinions recommendation of On the wrong DNA track: Molecular mechanisms of repeat-mediated genome instability.

J. Lowe, 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

Faculty of 1000 evaluation for Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers

J. Lowe, 2018 .

Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception.

J. Lowe, S. Welch, D. J. Mason, 1999, European journal of pharmacology.

Effects of the cannabinoid CB 1 receptor antagonist SR 141716 A on the behavior of pigeons and rats

J. Lowe, R. Mansbach, C. C. Rovetti, 2005 .

Faculty Opinions recommendation of Polypharmacology: challenges and opportunities in drug discovery.

John Lowe, J. Lowe, 2014 .

Partial Agonists of the α3β4* Neuronal Nicotinic Acetylcholine Receptor Reduce Ethanol Consumption and Seeking in Rats

R. Hurst, J. Lowe, S. Bartlett, 2011, Neuropsychopharmacology.

The Anxieties of Drug Discovery and Development

F. Lombardo, J. Lowe, L. Tremaine, 2002 .

Design of novel cholecystokinin-B receptor ligands based on the ‘double-ring system’ approach

J. Lowe, S. Mclean, J. Bordner, 1996, Regulatory Peptides.

5,7-Diphenyl-3-ureidohexahydroazepin-2-ones as Cholecystokinin-B receptor ligands

J. Lowe, S. Mclean, J. Bordner, 1994 .

Factors of sexual quality of life in gynaecological cancers: a systematic literature review

J. Lowe, A. Hamilton, Lisa Martin, 2021, Archives of Gynecology and Obstetrics.

Comparison of Steady‐State Blood Levels of Two Carbamazepine Formulations

J. Lowe, J. Lowe, R. Dasheiff, 1989, Epilepsia.

Selective inhibition of the carotid body sensory response to hypoxia by the substance P receptor antagonist CP-96,345.

J. Lowe, N. Prabhakar, R. Snider, 1993, Proceedings of the National Academy of Sciences of the United States of America.

The discovery of a structurally novel class of inhibitors of the type 1 glycine transporter.

J. Lowe, Xinjun Hou, L. Lebel, 2009, Bioorganic & medicinal chemistry letters.

Discovery of a novel Kv7 channel opener as a treatment for epilepsy.

Lei Zhang, R. J. Mather, Christopher R Butler, 2015, Bioorganic & medicinal chemistry letters.

A novel, non-substrate-based series of glycine type 1 transporter inhibitors derived from high-throughput screening.

J. Lowe, M. Peakman, C. Strick, 2007, Bioorganic & Medicinal Chemistry Letters.

An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter.

J. Lowe, S. Drozda, K. Ward, 2010, Bioorganic & medicinal chemistry letters.

Discovery heralds new approach to the treatment of cystic fibrosis.

J. Lowe, 2014, Journal of medicinal chemistry.

A new class of selective and potent inhibitors of neuronal nitric oxide synthase.

R. Volkmann, J. Lowe, M. Ashton, 1999, Bioorganic & Medicinal Chemistry Letters.

Faculty Opinions recommendation of Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology.

John Lowe, J. Lowe, 2018, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

Atypical Antipsychotics Based on the D2/S-HT2 Ratio Hypothesis

J. Lowe, 1994, Current Medicinal Chemistry.

Photoaffinity labeling of the human substance P (neurokinin-1) receptor with [3H2]azido-CP-96,345, a photoreactive derivative of a nonpeptide antagonist.

J. Lowe, S. Leeman, S. Drozda, 1996, Molecular Pharmacology.

Synthesis and structure-activity relationships of CP-122,721, a second-generation NK-1 receptor antagonist.

J. Lowe, M. Nakane, S. Mclean, 1998, Bioorganic & medicinal chemistry letters.

Faculty Opinions recommendation of Hit identification and optimization in virtual screening: practical recommendations based on a critical literature analysis.

John Lowe, J. Lowe, 2013 .

Faculty Opinions recommendation of Polypharmacology: challenges and opportunities in drug discovery.

J. Lowe, 2014 .